AGEN

5.9702.77%
JS

Jennifer S. Buell

Director and President & CEO of MiNK Therapeutics

Dr. Jennifer S. Buell, also known as Jen, Ph.D. is a Director at Agenus Inc since June 11, 2024. She had been Independent Director at Protagenic Therapeutics, Inc. since July 18, 2020. She is a Co-Founder of MiNK Therapeutics, Inc. Dr. Buell served as Chairman of the Board at MiNK Therapeutics, Inc. She is a Director at Agenus Inc. since June 11, 2024. She has been President, Chief Executive Officer and Director at Mink Therapeutics Inc. since February 2021. Dr. Buell was President of Agenus Inc. since January 2020 until December 31, 2021. She was Chief Operating Officer at Agenus Inc. since November 13, 2018 until December 31, 2021. She served as Chief Communications & External Affairs Officer at Agenus Inc. since September 26, 2017 until November 2018. She served as Vice President of Research and External Affairs at Agenus Inc. since April 4, 2017 until March 2018. Dr. Buell joined the Agenus Inc. on April 04, 2017. From September 2013 to August 2016, Dr. Buell was Agenus’ Vice President, Research and Development Operations and Program Management. She led Agenus’ clinical research and development operations and is responsible for immunotherapy products through early development activities to the clinic and advancing its late stage autologous cancer vaccine, Prophage. She has years of clinical development expertise in program management, clinical trial design and operational execution in immuno-oncology, neurology, auto-immunity and cardiovascular disease. With biopharmaceutical R&D experience, Dr. Buell has extensive knowledge in advancing discovery candidates through development and experience communicating with external stakeholders including regulators, Investors and collaborators. She has a proven record of success in R&D leadership, most recently at Agenus, where she led high performing teams in advancing candidates into the clinic and delivered on key alliance collaborations. Prior to joining Agenus, she was Senior Director of Program Management at Harvard Clinical Research and she held various leadership positions at Agenus, Worldwide Clinical Trials and Bristol-Myers Squibb. Since 2013, she has served Agenus as the Head of Global R&D operations, Head of Research and Chief External Affairs and Communications Officer. Prior to joining Agenus, Dr. Buell held leadership positions in R&D operations at Bristol-Myers Squibb and later was responsible for Program and Alliance Management at Harvard Clinical Research Institute (Baim), where she was involved in the development strategy and operations for a portfolio of industry and government sponsored clinical programs. During her tenure, she advanced the expansion of Agenus from a neoantigen vaccine company to a global, fully-integrated platform company with a unique pipeline of immune modulating antibodies, adoptive cell therapies, adjuvants and cancer vaccines. She holds a PhD in Cellular, Biochemical and Molecular Biochemistry and an MS in Biostatistics from Tufts University.

Positions